Literature DB >> 15618183

Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.

Christiane Beckmann1, Mitchell Brittnacher, Robert Ernst, Nicole Mayer-Hamblett, Samuel I Miller, Jane L Burns.   

Abstract

Pseudomonas aeruginosa airway infections are a major cause of morbidity and mortality in patients with cystic fibrosis. Treatment of established infections is difficult, even with microbiologically active agents. Thus, prevention of infection is an important goal of management. Isolates from cystic fibrosis patients appear to originate from the environment but adapt to the milieu of the airway of the cystic fibrosis patient and evolve toward a common phenotype. Identification of the antigens expressed early in infection may lead to novel targets for vaccine development. Immunogenic peptides were identified in a J404 random nonapeptide phage display library with serum from cystic fibrosis patients obtained within the first year of P. aeruginosa infection. One hundred sixty-five reactive clones were verified by plaque lift assays, and their inserts were sequenced. The sequenced nonapeptides were compared with the published sequence of strain PAO1, identifying homologies to 76 genes encoding outer membrane and secreted proteins. The majority of these were proteins involved in small-molecule transport, membrane structural proteins, and secreted factors. An in silico analysis was performed that suggested that the occurrence of multiple matches to predominantly outer membrane and secreted proteins was not attributable to random chance. Finally, gene expression array data from early isolates of P. aeruginosa from cystic fibrosis patients was compared with the results from phage display analysis. Eleven outer membrane and secreted proteins were common between the two data sets. These included genes involved in iron acquisition, antibiotic efflux, fimbrial biogenesis, and pyocin synthesis. These results demonstrate the feasibility and validity of this novel approach and suggest potential targets for future development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618183      PMCID: PMC538986          DOI: 10.1128/IAI.73.1.444-452.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Maintenance treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  N Høiby; C Koch
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

Review 2.  Filamentous phage display of oligopeptide libraries.

Authors:  J B Burritt; C W Bond; K W Doss; A J Jesaitis
Journal:  Anal Biochem       Date:  1996-06-15       Impact factor: 3.365

Review 3.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.

Authors:  S F Altschul; T L Madden; A A Schäffer; J Zhang; Z Zhang; W Miller; D J Lipman
Journal:  Nucleic Acids Res       Date:  1997-09-01       Impact factor: 16.971

Review 4.  Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease.

Authors:  G R Moe; S Tan; D M Granoff
Journal:  FEMS Immunol Med Microbiol       Date:  1999-12

5.  Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995).

Authors:  B Frederiksen; C Koch; N Høiby
Journal:  Pediatr Pulmonol       Date:  1999-09

6.  A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis.

Authors:  G Döring; F Dorner
Journal:  Behring Inst Mitt       Date:  1997-02

7.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

8.  Characterization of membrane-associated Pseudomonas aeruginosa Ras-like protein Pra, a GTP-binding protein that forms complexes with truncated nucleoside diphosphate kinase and pyruvate kinase to modulate GTP synthesis.

Authors:  B A Chopade; S Shankar; G W Sundin; S Mukhopadhyay; A M Chakrabarty
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

9.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Authors:  B W Ramsey; M S Pepe; J M Quan; K L Otto; A B Montgomery; J Williams-Warren; M Vasiljev-K; D Borowitz; C M Bowman; B C Marshall; S Marshall; A L Smith
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

10.  Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; A Lang; A Rüdeberg; J Wedgwood; J U Que; E Fürer; U Schaad
Journal:  Behring Inst Mitt       Date:  1997-02
View more
  29 in total

1.  Vanadate and triclosan synergistically induce alginate production by Pseudomonas aeruginosa strain PAO1.

Authors:  F Heath Damron; Michael R Davis; T Ryan Withers; Robert K Ernst; Joanna B Goldberg; Guangli Yu; Hongwei D Yu
Journal:  Mol Microbiol       Date:  2011-06-16       Impact factor: 3.501

2.  Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus.

Authors:  Ute Schwab; Lubna H Abdullah; Olivia S Perlmutt; Daniel Albert; C William Davis; Roland R Arnold; James R Yankaskas; Peter Gilligan; Heiner Neubauer; Scott H Randell; Richard C Boucher
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

Review 3.  Phage display--a powerful technique for immunotherapy: 2. Vaccine delivery.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

4.  Polymorphonuclear leukocytes restrict growth of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients.

Authors:  Kasper N Kragh; Morten Alhede; Peter Ø Jensen; Claus Moser; Thomas Scheike; Carsten S Jacobsen; Steen Seier Poulsen; Steffen Robert Eickhardt-Sørensen; Hannah Trøstrup; Lars Christoffersen; Hans-Petter Hougen; Lars F Rickelt; Michael Kühl; Niels Høiby; Thomas Bjarnsholt
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

5.  Identification of Dengue-specific B-Cell Epitopes by Phage-display Random Peptide Library.

Authors:  Nevis Amin; Alicia Aguilar; Frank Chamacho; Yaime Vázquez; Maritza Pupo; Juan Carlos Ramirez; Luis Izquierdo; Felix Dafhnis; David Ian Stott; Ela Maria Perez; Armando Acosta
Journal:  Malays J Med Sci       Date:  2009-10

6.  Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum.

Authors:  Kelli L Palmer; Stacie A Brown; Marvin Whiteley
Journal:  J Bacteriol       Date:  2007-03-30       Impact factor: 3.490

7.  PtrB of Pseudomonas aeruginosa suppresses the type III secretion system under the stress of DNA damage.

Authors:  Weihui Wu; Shouguang Jin
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

8.  Immunoproteomics to examine cystic fibrosis host interactions with extracellular Pseudomonas aeruginosa proteins.

Authors:  Hamish G Upritchard; Stuart J Cordwell; Iain L Lamont
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

9.  Proteomic, microarray, and signature-tagged mutagenesis analyses of anaerobic Pseudomonas aeruginosa at pH 6.5, likely representing chronic, late-stage cystic fibrosis airway conditions.

Authors:  Mark D Platt; Michael J Schurr; Karin Sauer; Gustavo Vazquez; Irena Kukavica-Ibrulj; Eric Potvin; Roger C Levesque; Amber Fedynak; Fiona S L Brinkman; Jill Schurr; Sung-Hei Hwang; Gee W Lau; Patrick A Limbach; John J Rowe; Michael A Lieberman; Nicolas Barraud; Jeremy Webb; Staffan Kjelleberg; Donald F Hunt; Daniel J Hassett
Journal:  J Bacteriol       Date:  2008-01-18       Impact factor: 3.490

10.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.